---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-126749"
form_type: "8-K"
ticker: "ALXO"
cik: "0001810182"
company_name: "ALX ONCOLOGY HOLDINGS INC"
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:34:36.545739+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ALX Oncology appoints Alan Sandler as CMO; CFO Garcia departs with separation agreement

## Summary
- Alan Sandler, M.D., appointed Chief Medical Officer effective Nov 10, 2024; base salary $575k, signing bonus $50k, 700k stock options.
- Former CFO Peter Garcia resigned Nov 8, 2024; receives $479,646 lump sum, COBRA for 12 months, accelerated equity vesting, and consulting role.
- Board reduced to 4 directors; committees set: Audit (Hemrajani chair), Compensation (Goodman chair), Governance (Garland chair).
- Dr. Sandler brings 30+ years experience from Mirati, Genentech, Zai Lab; will lead evorpacept development into late-stage trials.

## SEC filing metadata
- accession: 0000950170-24-126749
- form_type: 8-K
- ticker: ALXO
- cik: 0001810182
- company_name: ALX ONCOLOGY HOLDINGS INC
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810182/000095017024126749/0000950170-24-126749-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810182/000095017024126749/alxo-20241108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-126749
- JSON: https://secwatch.observer/filing/0000950170-24-126749.json
- Plain text: https://secwatch.observer/filing/0000950170-24-126749.txt

## Key facts
- Executive change
  Alan Sandler resigned as member of the Board at ALX ONCOLOGY HOLDINGS INC.
  - Action: resigned
  - Role: member of the Board
  source text: Effective on the same date, Dr. Sandler resigned as a member of the Board and all committees thereof.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1810182/000095017024126749/0000950170-24-126749-index.htm
- Executive change
  Peter Garcia resigned as Chief Financial Officer at ALX ONCOLOGY HOLDINGS INC.
  - Action: resigned
  - Role: Chief Financial Officer
  source text: As previously disclosed, Peter Garcia resigned as Chief Financial Officer of the Company effective November 8, 2024, due to personal reasons.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1810182/000095017024126749/0000950170-24-126749-index.htm
- Executive change
  Alan Sandler was appointed as Chief Medical Officer at ALX ONCOLOGY HOLDINGS INC.
  - Action: appointed
  - Role: Chief Medical Officer
  source text: On November 10, 2024, the Board of Directors (the “Board”) of ALX Oncology Holdings Inc. (the “Company”) appointed Alan Sandler, M.D., age 68, to the office of Chief Medical Officer to fill a recently created vacancy.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1810182/000095017024126749/0000950170-24-126749-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.